GlassScriptPhysician profile
Genene P Radden
NPI 1710917422
$3,917.88
in general payments reported to CMS, 2019-2025
18 companies · $313 in 2025
The $313 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $901 · 2020: $133 · 2021: $511 · 2022: $765 · 2023: $668 · 2024: $628 · 2025: $313.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,579 · Education: $29.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,579.12 |
| Education | $29.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,290.30 | 2019-2025 | Enbrel, Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $916.70 | 2019-2025 | |
| Celgene Corporation | $507.79 | 2019 | |
| Ucb, INC. | $256.55 | 2019-2025 | Cimzia, Bimzelx |
| Abbvie INC. | $209.25 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $123.71 | 2021 | |
| Lilly USA, LLC | $118.66 | 2019-2024 | Taltz |
| Astrazeneca Pharmaceuticals LP | $81.19 | 2022-2024 | Saphnelo |
| Genzyme Corporation | $74.27 | 2024-2025 | |
| Glaxosmithkline, LLC. | $58.38 | 2022-2023 | Benlysta |
| Pfizer INC. | $56.78 | 2019-2023 | |
| Genentech USA, INC. | $54.13 | 2022-2025 | Actemra |
| E.R. Squibb & Sons, L.L.C. | $46.72 | 2019-2024 | Orencia |
| Janssen Biotech, INC. | $43.68 | 2019-2024 | Tremfya |
| Fresenius Kabi USA, LLC | $24.60 | 2023 | Idacio |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $20.71 | 2023 | Lupkynis |
| Medexus Pharma, INC. | $19.42 | 2019 | |
| Alexion Pharmaceuticals, INC. | $15.04 | 2024 | Ultomiris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Genene Radden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.